Skip to content Skip to footer
Subscribe Now
Cue Biopharma & Boehringer Ingelheim
NEWS

Cue Biopharma Collaborates with Boehringer Ingelheim to Develop B cell-Targeting Bispecifics for Autoimmune and Inflammatory Diseases

Shots: BI & Cue Biopharma have entered into a multi-year strategic research & license agreement to develop & commercialize CUE-501 for autoimmune diseases, with the potential to expand into other B cell-targeting bispecifics using Cue’s Immuno-STAT platform As per the deal, Cue Biopharma will receive a $12M upfront & ~$345M in research, development, & commercial…
April 15, 2025

Read more

Viewpoints_Anish Suri
VIEWPOINTS

PharmaShots Interview: Cue Biopharma’s Anish Suri Shares Insights on the Data of CUE-401 Presented at 2021 FOCIS Annual Meeting

In an interview with PharmaShots, Anish Suri, Ph.D., President, and Chief Scientific Officer at Cue Biopharma shared his views on new preclinical data of CUE-401 for the treatment of autoimmune diseases at the 2021 FOCIS Annual Meeting Shots: The company has reported the preclinical data of CUE-401 which can induce & expand regulatory T cells in vitro and in vivo & has the potential to…
October 15, 2021

Read more